CYTK Q4 2019 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-44.4% YoY

Gross Profit

-$13M-251.8% margin

Operating Income

-$24M-454.8% margin

Net Income

-$31M-587.9% margin

EPS (Diluted)

$-0.52

QoQ Revenue Growth

-13.9%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$20M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$290M

Total Liabilities

$301M

Stockholders' Equity

-$11M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$9M	-44.4%
Gross Profit	-$13M	-$14M	+5.6%
Operating Income	-$24M	-$21M	-10.5%
Net Income	-$31M	-$26M	-15.8%

Revenue Segments

Research And Development

$5M100%